Clinical Trial Update: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Ublituximab + TGR-1202 versus Obinutuzumab + Chlorambucil in untreated and previously treated chronic lymphocytic leukemia was terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Chlorambucil (chlorambucil)
• Obinutuzumab (obinutuzumab)
• TGR-1202 (umbralisib)
• Ublituximab (ublituximab)

Snippet

Sponsor: TG Therapeutics, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2024-05-07